(Q37200093)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24109519%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

title

Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24109519%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24109519%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Areg Totolian

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24109519%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

8

Amit Bar-Or

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24109519%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

author name string

Evgeniy Evdoshenko

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24109519%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Alexey Maslyanskiy

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24109519%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Sergey Lapin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24109519%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Leonid Zaslavsky

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24109519%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

Alexander Skoromets

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24109519%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

publication date

10 September 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24109519%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24109519%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

volume

2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24109519%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

page(s)

748127

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24109519%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 3.0 Unported

27 February 2020

copyright license

start time

10 September 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

Chemotherapeutics in the treatment of multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

Current and Future Role of Interferon Beta in the Therapy of Multiple Sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

Induction vs. escalating therapy in multiple sclerosis: practical implications

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

Treating multiple sclerosis in the natalizumab era: risks, benefits, clinical decision making, and a comparison between North American and European Union practices.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

Immunopathogenesis of multiple sclerosis: concepts and controversies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

B-cells in multiple sclerosis.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

Suppression of experimental allergic encephalomyelitis by mitoxantrone.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

[Mitoxantrone for the treatment of patients with multiple sclerosis].

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

Rituximab-associated immune myelopathy

3 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1155%2F2013%2F748127

Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1155%2F2013%2F748127

Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3784158

Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells

4 December 2018

1 reference

12 December 2020

Iso-electric focusing of aqueous humour IgG in multiple sclerosis

1 reference

12 December 2020

Rituximab in ANCA-associated vasculitis: fad or fact?

1 reference

12 December 2020

Is Rituximab Superior to Cyclophosphamide for ANCA-Associated Vasculitis for Induction of Remission, and with a Better Safety Profile?

1 reference

12 December 2020

Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases

1 reference

12 December 2020

Vasculitis: Rituximab: effective in ANCA-associated vasculitis?

1 reference

12 December 2020

Neutropenia in patients treated with rituximab

1 reference

12 December 2020

Identifiers

DOI

10.1155/2013/748127

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24109519%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24109519%20AND%20SRC:MED&resulttype=core&format=json

27 February 2020

PubMed publication ID

24109519

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24109519%20AND%20SRC:MED&resulttype=core&format=json